您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > ML-297
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
ML-297
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
ML-297图片
CAS NO:1443246-62-5
包装与价格:
包装价格(元)
10mg电议
50mg电议

产品介绍

化学性质

Physical AppearanceA crystalline solid
StorageStore at -20°C
M.Wt328.3
Cas No.1443246-62-5
FormulaC17H14F2N4O
SynonymsCID-56642816,VU0456810
Solubility≤20mg/ml in ethanol;30mg/ml in DMSO;30mg/ml in dimethyl formamide
Chemical NameN-(3,4-difluorophenyl)-N'-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-urea
Canonical SMILESO=C(NC1=CC(F)=C(F)C=C1)NC2=CC(C)=NN2C3=CC=CC=C3
运输条件蓝冰运输或根据您的需求运输。
一般建议为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。

资料参考

EC50: 0.16 and 1.8 μM for GIRK1/2 and GIRK1/4, respectively.

ML-297 is a selective Kir3.1/3.2 (GIRK1/2) channel activator.

G protein-regulated inwardly rectifying potassium (GIRK1-4) channels are a family of Kir3.1-Kir3.4 ion channels modulating cell excitability. The four different GIRK subunits are composed in different combinations expressed with regional specificity throughout the central nervous system and in the periphery.

In vitro: In thallium flux assays, ML297 showed concentration-dependent efficacy when tested on cells expressing GIRK1/2. ML297 could also activate GIRK channels comprised of GIRK1/3 and GIRK1/4 subunit combinations. However, ML297 diaplayed a complete inability to modulate the activity of HEK-293 cells expressing GIRK2 alone. A similar complete lack of efficacy was seen when ML297 was tested on HEK-293 cells expressing GIRK2/3. Therefore, it appeared that ML297 is only capable of activating GIRK channels containing a GIRK1 subunit [1].

In vivo: Previous study performed an ascending dose study in mice and it was found that the animals appeared normal and not under obvious distress at all doses tested. ML297’s effects on locomotor activity as well as effects on motor function and coordination were further evaluated. Results showed that ML297 at 60 mg/kg could immediate decrease in locomotor activity compared to the control group [1].

Clinical trial: So far, no clinical study has been conducted.

Reference:
[1] Kaufmann, K. ,Romaine, I.M.,Days, E., et al. ML297 (VU0456810), the first potent and selective activator of the GIRK potassium channel, displays antiepileptic properties in mice. ACS Chem.Neurosci. 4(9), 1278-1286 (2013).